CSI Market
Sign In | Register

Fibrocell Science (FCSC) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access FCSC quarterly Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Fibrocell Science funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2018)
12 Months 		(Dec 31 2017) (Dec 31 2016) (Dec 31 2015) (Dec 31 2014)
Operating Activities
Income-10.28
Depreciation & amortization0.39
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Impairment of Intangible Assets, Finite-lived0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.53
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Reorganization Items Net-
Warrant Income Expense-
Uncompensated Contribution Of Services-
Investment Income Amortization Of Discount-
Loss On Disposal Or Impairment Of Property And Equipment-
Foreign Exchange Gain Loss On Substantial Liquidation Of Foreign Entity-
Warrant Income-
Payments For Derivative Revaluation-
Adjustments To Reconcile Net Loss Stock Issued For Exclusive Channel Collaboration Agreement-
Adjustments For Loss Stock Issued For Collaboration Agreement With Related Party-
Warrant Revaluation And Other Finance Income Or Expense-0.92
Warrant Revaluation Income Expense-
Allowance For Doubtful Accounts Receivable Period Increase Decrease-
Increase Decrease In Operating Lease Liability-
Gain Losson Disposalor Impairment of Property Plant Equipment-
Income taxes0.00
Unrealized Gain (Loss) on Derivatives-1.66
Increase (Decrease) in Accounts Receivable0.00
Accounts Payable-2.23
Accrued Expense1.03
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.38
Other Working Capital0.04
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-12.72
Investing Activities
Capital Expenditures-0.16
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Proceeds from Divestiture of Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.16
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.44
Long-term debt - borrowings0.90
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock8.92
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.02
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.85
Offering Costs Associated With Issuance Of Debt-
Proceeds From Debtor In Possession Loan-
Payments On Insurance Loan-
Principal Payments On Note Payable-
Cash Paid For Fractional Shares Of Preferred Stock-
Proceeds From Common Stock Subscriptions Received-
Proceeds From Subscription Received-
Proceeds from Conversion of Common Warrants0.50
Decreasein Accrued Interest Payable-
Decrease In Derivative Liability-
Debt Conversion Converted Instrument Amount-
Dividends Preferred Stock Paidinkind0.34
Preferred Stock Deemed Dividend0.51
Payments of Ordinary Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities9.89
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-12.88
Total Cash Flow-2.99
4 historic quarters locked

Sign in to unlock the full Fibrocell Science cash flow history.

Sign In Create Free Account

About FCSC Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License